Merck Animal Health to Present Important New Data at the World Buiatrics Congress

Data to Focus on Bovine Respiratory and Reproductive Health

MADISON, N.J., June 6, 2016 –Merck Animal Health (known as MSD Animal Health outside the USA and Canada) will present 45 studies at the World Buiatrics Congress in Dublin, Ireland, from July 3-8, 2016. The majority of presentations will focus on the increasingly important cattle respiratory and reproductive health.

“Merck Animal Health is committed to advancing the science of healthier animals by providing comprehensive solutions to protect herd health throughout the lifecycle,” said Dr. Jantijn Swinkels, Global Technical Director, Ruminants, Merck Animal Health. “We are pleased to share important new data to help producers across the globe advance how they treat and prevent some of the most serious and economically damaging diseases affecting cattle.”

Selected topics will be featured on the company’s video channel, StudioBovine. To learn more about Merck Animal Health, visit the company’s website or follow us on LinkedIn. For more information about the World Buiatrics Congress, visit

Abstracts selected for oral and poster presentations are as follows.

Oral Presentations

Respiratory Health

  • Intranasal vaccination in the face of maternal antibody induces long-term mucosal immune memory (July 5, 10:45-11:00 a.m.)
  • Comparison of two macrolides in the control of BRD in calf ranch cattle (July 7, 9:15-9:30 a.m.)
  • Efficacy of flunixin meglumine pour-on administration in a tissue cage model of inflammation (July 7, 9:30-9:45 a.m.)
  • Early detection of bovine respiratory disease and immediate treatment with flunixin help to reduce the use of antibiotics in beef calves (July 7, 9:45-10:00 a.m.)
  • Treatment of naturally occurring bovine respiratory disease in juvenile calves with a single administration of a florfenicol plus flunixin meglumine formulation (July 7, 11:30-11:45 a.m.)
  • Associations between lung consolidation, bovine respiratory disease treatment and live-weight in UK veal cattle (July 7, 11:45 a.m.-12:00 p.m.)
  • Effectiveness of tildipirosin and tulathromycin in the control of bovine respiratory disease in high-risk beef heifers (July 7, 12:30-12:45 p.m.)
  • Failure to define the aetiology of acute pneumonia cases in live dairy cows (July 5 15.15-15.30 p.m.)

Neonatal Health

  • On farm monitoring of the four Q’S of colostrum management is important (July 7, 12:00-12:15 p.m.)

Other Topics

  • There is a need to raise farmers’ awareness of correct vaccine storage temperatures (July 5, 10:30-10:45 a.m.)
  • Systematic review and meta-analysis of the effectiveness of cefquinome therapeutic schemes for the treatment of clinical mastitis in bovine (July 4th, 15.45-16.00 p.m.)

Poster Presentations

Respiratory Health

  • Flunixin meglumine transdermal pour-on solution as adjunct therapy in the treatment of bovine respiratory disease in calves less than 8 weeks of age (Thursday, July 7th)
  • Efficacy of injectable florfenicol plus flunixin combination against an experimentally induced Mycoplasma bovis infection in calves (Thursday, July 7th)
  • Field prevalence of bovine respiratory pathogens by PCR technique in France (Wednesday, July 6th)
  • Pulmonary lesions and clinical disease in Histophilus somni-challenged calves treated with, either tildipirosin or tulathromycin (Thursday, July 7th)
  • Incidence and antibiotic susceptibility of non-viral pathogens isolated from calves with BRD (Thursday, July 7th)
  • Comparative time, behavior and economic differences associated with calves receiving a flunixin pour-on vs. an intravenous product (Tuesday, July 5th)


  • Resumption of ovarian cyclicity and energy balance in Holstein cows in France based on in-line milk measurements (Wednesday, July 6th)
  • Protocols combining GnRH and a prostaglandin analogues for the treatment of ovarian cysts in dairy cows (Tuesday, July 5th)
  • Efficacy of 86μg gonadorelin and cloprostenol sodium in a dairy fixed-time artificial insemination program (Wednesday, July 6th)
  • Effect of two different bovine somatotropins on milk yield and reproduction of dairy cows in Brazil (Wednesday & Thursday, July 6 and 7th)
  • Absence of association between pre and post-partum energy status and genital inflammation in dairy cows (Tuesday, July 5th)
  • Equine chorionic gonadotropin treatment in a fixed-time artificial insemination protocol in anestrus beef cows (Tuesday, July 5th)
  • One single dose of equine chorionic gonadotropin is sufficient for superovulation of cows (Tuesday, July 5th)

Udder Health

  • Antimicrobial susceptibility of staphylococcus aureus isolated in bovine mastitis in France (Thursday, July 7th)
  • Effectiveness and safety of a novel flunixin meglumine transdermal pour-on solution in the treatment of bovine mastitis (Monday, July 4th)
  • Intramammary prednisolone treatment of naturally occurring clinical mastitis only increased clinical cure in mild mastitis (Monday, July 4th)

Bovine Viral Diarrhea Virus

  • Monitoring of BVDV by testing antibodies to NS3 protein in calves vaccinated with an inactivated BVDV vaccine (Wednesday, July, 6th)
  • Does BVD vaccination of recently weaned pasture-fed beef cattle prevent weight loss when exposed to persistently infected cattle? (Tuesday, July, 5th)
  • Molecular epidemiology of bovine viral diarrhoea virus in Spain (Wednesday, July, 6th)


  • Fipronil and Fluazuron: efficacy of a novel parasiticide combination against Dermatobia hominis and Cochliomyia hominivorax in naturally infested cattle (Thursday, July, 7th)
  • Pharmacokinetic evaluation of a new combination of Fipronil and Fluazuron topically administered (pour-on) in cattle (Thursday, July, 7th)
  • Therapeutic and residual efficacy of a novel Fluazuron combination against Rhipicephalus (Boophilus) microplus in naturally infested cattle (Thursday, July, 7th)
  • Comparative therapeutic and residual efficacy of a novel parasiticide combination of Fibronil and Fluazuron against Rhipicephalus (Boophilus) microplus ticks in artificially infested cattle (Thursday, July 7th)

Neonatal Health

  • Evaluation of quality and management of colostrum on dairy farms in Spain (Thursday, July 5th)
  • Improving colostrum management in dairy calves by blood IgG measurement combined with recording colostrum management data (Thursday, July, 5th)
  • The healthy calf – a nationwide survey examining the IgG concentrations in newborn calves (Tuesday, July 5th)

Animal Welfare

  • Education of the dairy employee on animal care – A practical approach using Dairy CARE 365 (Tuesday, July 5th)


  • Evolution of seroprevalence for BHV-1 gE in a French herd vaccinated with a live bovine herpesvirus type 1 marker vaccine (Monday, July 4th)
  • Vaccination against clostridial disease in maternally derived antibodiespositive lambs; a randomised, non-inferiority field trial in twin lambs (Tuesday, July 5th)
  • Vaccination intramuscularly in the neck vs subcutaneously into the ischiorectal fossa: A non-inferiority study comparing serological and colostral immunity, and tissue reactivity in cows vaccinated with a combined vaccine against rotavirus, coronavirus and E. coli F5 (K99) vaccine (Tuesday, July 5th)
  • Vaccination of dairy cows in late gestation: effect on serum and colostrum antibody titers for BRSV and Mannheimia haemolytica (Tuesday, July 5th)

Other topics

  • Digital communication and knowledge transfer for veterinary practitioners and their client animal owners in Ireland (Monday, July 4th)
  • Validation of an easy-to-use device for non-esterified fatty acids assay in blood in dairy cattle (Tuesday, July 5th)

About Studio Bovine™
An initiative of Merck Animal Health (known as MSD Animal Health outside the US and Canada), Studio Bovine is dedicated to broadcasting knowledge and farm intelligence in bovine health and productivity. Through online video interviews with leading experts, Studio Bovine is committed to examining complete solutions, equipping veterinarians and farmers with up-to-date and actionable information on issues such as handling, preventive medicine, treatment strategies and performance solutions. Studio Bovine is intended as a platform for interaction and exchange within the global community of bovine professionals. The goal: a shared, integrated vision on Bovine health, sustainability, productivity and quality. For more information and additional video features, please visit

About Merck Animal Health
For 125 years, Merck has been a global health care leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedInFacebook and Twitter at @MerckAH.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (